Clinical bottom line
Circulating tumor DNA (ctDNA) analysis is an emerging tool for guiding treatment adaptation in advanced pancreatic cancer, a malignancy with historically poor prognosis and limited therapeutic options. Recent advances in ctDNA detection, including targeted DNA methylation sequencing and fragmentomics, have improved sensitivity for tumor-agnostic detection in this setting. Preliminary evidence suggests that ctDNA dynamics may predict treatment response and enable earlier therapy modification compared to conventional imaging or serum markers. However, clinical utility remains investigational, and integration into routine practice requires further validation in prospective trials.
What the evidence shows
Pancreatic cancer is characterized by aggressive biology and rapid progression, often limiting the window for effective treatment adaptation. Botiralieva et al. (2018) demonstrated that ctDNA levels correlated with treatment response in locally advanced pancreatic cancer, with rising ctDNA predicting disease progression earlier than radiographic changes. More recently, advanced methodologies combining targeted DNA methylation sequencing with cell-free DNA fragmentomics have enabled tumor-agnostic ctDNA detection with improved sensitivity and specificity in advanced pancreatic cancer patients [2]. These approaches capture epigenetic and fragmentation signatures that are less dependent on tumor-specific mutations, addressing challenges posed by pancreatic tumors’ low mutational burden.
The ability to monitor ctDNA kinetics longitudinally offers a dynamic biomarker to guide treatment adaptation. For example, early decreases in ctDNA after chemotherapy initiation have been associated with better outcomes, while persistent or rising ctDNA may indicate resistance and the need for regimen change (Botiralieva et al., 2018). This concept parallels findings in other cancers, such as advanced esophageal cancer, where ctDNA-guided treatment decisions have shown promise in ongoing studies [4]. Although direct evidence in pancreatic cancer remains limited, these data support the hypothesis that ctDNA-guided adaptation could optimize therapeutic sequencing and avoid ineffective treatments.
Caveats and uncertainty
Despite encouraging signals, ctDNA-guided treatment adaptation in advanced pancreatic cancer is not yet standard of care. Sensitivity remains variable, especially in patients with low tumor burden or limited ctDNA shedding. The heterogeneity of pancreatic tumors and the presence of non-tumor-derived cfDNA fragments can complicate interpretation. Furthermore, the clinical impact of changing therapy based on ctDNA dynamics has not been conclusively demonstrated in randomized trials.
Most available data derive from small cohorts or retrospective analyses, limiting generalizability. The optimal timing and thresholds for ctDNA measurement to inform treatment decisions are not standardized. Additionally, the cost and accessibility of advanced ctDNA assays, including methylation and fragmentomics techniques, may restrict widespread implementation. Integration with existing clinical and radiographic assessments requires prospective validation to confirm added value.
How this may change practice
If validated, ctDNA-guided treatment adaptation could transform management of advanced pancreatic cancer by enabling real-time, minimally invasive monitoring of tumor response and resistance. This approach may facilitate earlier identification of non-responders, allowing prompt switches to alternative therapies or enrollment in clinical trials. It could also reduce reliance on imaging, which is often limited by pancreatic tumor location and desmoplastic stroma.
Clinicians should remain informed about emerging ctDNA technologies and consider participation in clinical studies evaluating their utility. In the near term, ctDNA analysis may serve as a complementary biomarker to support clinical judgment rather than replace standard assessments. Ongoing research will clarify how best to integrate ctDNA-guided strategies into multidisciplinary care pathways to improve outcomes in this challenging disease.